頁籤選單縮合
題 名 | 藥物引起肝傷害之藥害救濟案例=Drug-Induced Liver Injury in Taiwan--Drug Injury Relief Foundation Database |
---|---|
作 者 | 遲蘭慧; | 書刊名 | 藥學雜誌 |
卷 期 | 30:2=119 2014.06[民103.06] |
頁 次 | 頁11-15 |
分類號 | 418.1 |
關鍵詞 | 藥物性肝傷害; 抗結核菌; B型肝炎; 藥害救濟; 藥物不良反應; Drug-induced liver injury; Antituberculosis; Hepatitis B; Adverse drug reactions; Drug injury relief; |
語 文 | 中文(Chinese) |
中文摘要 | 藥物性肝傷害 (drug-induced liver injury, DILI) 為許多國家發生急性肝傷害之主要 原因,也因其為嚴重之藥物不良反應,成為近年來美國食品藥物管理局進行藥品之回 收或撤市原因排名第一位。常見引發 DILI 之藥品包含 acetaminophen 及抗結核菌藥 (anti-tuberculosis treatment, ATT) 等。故本文將就台灣藥害救濟案例資料庫內,疑似藥 物引起肝傷害之相關案例進行分析,探討此藥物不良反應發生型態,及與各可能危險 因子之相關性,提供臨床醫療人員於處方藥物及監測並預防此不良反應發生之本土性 資料。 |
英文摘要 | Drug-induced liver injury (DILI) is the major cause of acute liver injury in the US and many other countries. It is also the most common reason for withdrawing an approved drug in the US. The non-prescription acetaminophen overdose is the most common drug induced liver injury in the US in the and northern Europe, and the second one is anti-tuberculosis treatment (ATT) medications. In the past decades, DILI has become the important adverse drug reactions (ADRs) attributed to the drug relief payment in Taiwan. We analyzed and reported the serious cases results from drug injury relief applications. This article may provide appropriate information and strategies to health care professionals about how to avoid further preventable miseries. |
本系統中英文摘要資訊取自各篇刊載內容。